Paget’s disease of Bone - Pipeline Assessment and Market Forecasts to 2017

Paget’s disease of Bone - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Paget’s disease of Bone - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Paget’s disease of Bone market. The report identifies the key trends shaping and driving the global Paget’s disease of Bone market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Paget’s disease of Bone sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis reveals that the Paget’s disease of bone market was worth $678m in 2009. It is forecast to exhibit a negative compound annual growth rate (CAGR) of 5% for the next eight years and is expected to reach $463m by 2017. The negative growth rate is primarily attributable to the patent expiry of major approved drugs and a weak pipeline for the indication. Furthermore, a substantial decrease in the prevalence of Paget’s disease of bone will lead to a drop in the global prescription population. The market will witness generic erosion owing to the patent expiry of products such as Actonel Reclast and Miacalcin. The market has been steadily declining over the past few years and this trend is likely to continue

Scope

The report provides information on the key drivers and challenges of the Paget’s disease of Bone market. Its scope includes:

• Annualized global Paget’s disease of Bone market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Antagonist of Wnt Signaling and osteoclast activity inhibitor.
• Analysis of the current and future competition in the global Paget’s disease of Bone market. Key market player covered is Genta Incorporated.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Paget’s disease of Bone therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Paget’s disease of Bone market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Paget’s disease of Bone market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Paget’s disease of Bone market landscape? - Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 PAGET’S DISEASE OF BONE: MARKET CHARACTERIZATION

2.1 Overview
2.2 GlobalData Pipeline Report Guidance

3 PAGET’S DISEASE OF BONE THERAPEUTICS MARKET: MARKET CHARACTERIZATION

3.1 Paget’s Disease of Bone Therapeutics Market Size
3.2 Paget’s Disease of Bone Therapeutics Market Forecast and CAGR
3.3 Drivers and Barriers for the Paget’s Disease of Bone Therapeutics Market
  3.3.1 Drivers for the Paget’s Disease of Bone Therapeutics Market
  3.3.2 Barriers of the Paget’s Disease of Bone Therapeutics Market
3.4 Opportunity and Unmet Need
3.5 Key Takeaway

4 PAGET’S DISEASE OF BONE THERAPEUTICS MARKET: COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Paget’s Disease of Bone Therapeutics Market
  4.3.1 Risedronate sodium (Actonel)
  4.3.2 Alendronate sodium (Fosamax)
  4.3.3 Zoledronic Acid (Reclast/Aclast)
  4.3.4 Pamidronate Disodium (Aredia)
  4.3.5 Tiludronate disodium (Skelid)
  4.3.6 Salmon calcitonin (Miacalcin)
4.4 Key Takeaway

5 PAGET’S DISEASE OF BONE: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 Paget’s disease of bone Therapeutics – Promising Drugs under Clinical Development
  5.3.1 Oral Gallium
5.4 Paget’s Disease of Bone Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 Paget’s Disease of Bone Pipeline – Pipeline by Clinical Phases of Development
  5.5.1 Paget’s Disease of Bone Therapeutics – Phase II Clinical Pipeline
  5.5.2 Paget’s Disease of Bone Therapeutics – Preclinical Pipeline
5.6 Discontinued / Suspended Drugs for Paget’s Disease of Bone
5.7 Key Takeaway

6 PAGET’S DISEASE OF BONE THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 PAGET’S DISEASE OF BONE THERAPEUTICS MARKET: FUTURE PLAYERS IN THE PAGET’S DISEASE OF BONE THERAPEUTICS MARKET

7.1 Introduction
7.2 Genta Incorporated

8 PAGET’S DISEASE OF BONE THERAPEUTICS MARKET: APPENDIX

8.1 Market Definitions
8.2 KOL Interviews
8.3 Acronyms
8.4 Research Methodology
  8.4.1 Coverage
  8.4.2 Secondary Research
  8.4.3 Forecasting
  8.4.4 Primary Research
  8.4.5 Expert Panel Validation
8.5 Contact Us
8.6 Disclaimer
8.7 Sources 31

LIST OF TABLES

Table 1: Paget’s Disease of Bone Therapeutics Market, Global, Revenue ($m), 2001–2009
Table 2 Paget’s Disease of Bone Therapeutics Market, Global, Market Forecasts ($m), 2009–2017
Table 3: Paget’s Disease of Bone Therapeutics Market, Strategic Competitor Assessment of the Major Marketed Products, 2010
Table 4: Paget’s Disease of Bone Therapeutics Market, Current Major Products, 2010
Table 5: Paget’s disease of bone Therapeutics – Promising Drugs Under Clinical Development, 2010
Table 6: Paget’s Disease of Bone Therapeutics – Phase II Clinical Pipeline, 2010
Table 7: Paget’s Disease of Bone Therapeutics Market, Preclinical Pipeline, 2010
Table 8: Paget’s Disease of Bone Therapeutics Market, List of Discontinued Drugs, 2010 22

LIST OF FIGURES

Figure 1: Paget’s Disease of Bone Therapeutics Market, Global, Revenues ($m), 2001-2009
Figure 2: Paget’s Disease of Bone Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2017
Figure 3: Opportunity and Unmet Need in the Paget’s Disease of Bone Therapeutics Market
Figure 4: Paget’s Disease of Bone Therapeutics Market, Technology Trends Analytic Framework of the Pipeline, 2010
Figure 5: Paget’s Disease of Bone Therapeutics Market, Technology Trends Analytic Framework of Pipeline, Description, 2010
Figure 6: Paget’s Disease of Bone Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2010
Figure 7: Paget’s Disease of Bone Therapeutics Market, Pipeline by Phase of Clinical Development (%), 2010
Figure 8: Paget’s Disease of Bone Therapeutics Market, Global, Implications for Future Market Competition, 2010
Figure 9: Paget’s Disease of Bone Therapeutics Market, Clinical Pipeline by Company, 2010
Figure 10: GlobalData Market Forecasting Model 29

COMPANIES MENTIONED

Genta Incorporated Skip to top